Literature DB >> 34348413

Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.

Sandeep M Nayak1, Natalie Gukasyan1, Frederick S Barrett1, Earth Erowid2, Fire Erowid2, Roland R Griffiths1,3.   

Abstract

INTRODUCTION: Psychedelics show promise in treating unipolar depression, though patients with bipolar disorder have been excluded from recent psychedelic trials. There is limited information on the use of classic psychedelics (e. g., LSD or psilocybin) in individuals using mood stabilizers to treat bipolar disorder. This is important to know, as individuals with bipolar depression may attempt to treat themselves with psychedelics while on a mood stabilizer, particularly given enthusiastic media reports of the efficacy of psilocybin for depression.
METHODS: This study analyzed reports of classic psychedelics administered with mood stabilizers from 3 websites (Erowid.org, Shroomery.org, and Reddit.com).
RESULTS: Strikingly, 47% of 62 lithium plus psychedelic reports involved seizures, and an additional 18% resulted in bad trips while none of 34 lamotrigine reports did. Further, 39% of lithium reports involved medical attention. Most of the lamotrigine reports (65%) but few (8%) of the lithium reports were judged to not affect the psychedelic experience. DISCUSSION: Although further research is needed, we provisionally conclude that psychedelic use may pose a significant seizure risk for patients on lithium. Thieme. All rights reserved.

Entities:  

Year:  2021        PMID: 34348413     DOI: 10.1055/a-1524-2794

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  9 in total

Review 1.  Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.

Authors:  David Bender; David J Hellerstein
Journal:  Psychopharmacology (Berl)       Date:  2022-01-13       Impact factor: 4.530

2.  Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience.

Authors:  David Wyndham Lawrence; Robin Carhart-Harris; Roland Griffiths; Christopher Timmermann
Journal:  Sci Rep       Date:  2022-05-24       Impact factor: 4.996

Review 3.  Psychedelics in the treatment of unipolar and bipolar depression.

Authors:  Oliver G Bosch; Simon Halm; Erich Seifritz
Journal:  Int J Bipolar Disord       Date:  2022-07-05

Review 4.  Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico.

Authors:  Snehal R Bhatt; Maya Armstrong; Tassy Parker; Marcello Maviglia; Rebecca Kass; Lawrence Leeman; Paul Romo; Douglas Ziedonis
Journal:  Front Pharmacol       Date:  2022-06-27       Impact factor: 5.988

Review 5.  Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review.

Authors:  Aryan Sarparast; Kelan Thomas; Benjamin Malcolm; Christopher S Stauffer
Journal:  Psychopharmacology (Berl)       Date:  2022-03-07       Impact factor: 4.415

Review 6.  The Potential of Psychedelics for End of Life and Palliative Care.

Authors:  David B Yaden; Sandeep M Nayak; Natalie Gukasyan; Brian T Anderson; Roland R Griffiths
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 7.  Psychedelic Therapy's Transdiagnostic Effects: A Research Domain Criteria (RDoC) Perspective.

Authors:  John R Kelly; Claire M Gillan; Jack Prenderville; Clare Kelly; Andrew Harkin; Gerard Clarke; Veronica O'Keane
Journal:  Front Psychiatry       Date:  2021-12-17       Impact factor: 4.157

8.  Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD).

Authors:  Emma I Kopra; Jason A Ferris; James J Rucker; Benjamin McClure; Allan H Young; Caroline S Copeland; Adam R Winstock
Journal:  J Psychopharmacol       Date:  2022-06-07       Impact factor: 4.562

9.  Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms.

Authors:  Emma I Kopra; Jason A Ferris; Adam R Winstock; Allan H Young; James J Rucker
Journal:  J Psychopharmacol       Date:  2022-04-07       Impact factor: 4.562

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.